• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial.

作者信息

Bitran J D

出版信息

Cancer. 1985 Nov 15;56(10):2420-3. doi: 10.1002/1097-0142(19851115)56:10<2420::aid-cncr2820561014>3.0.co;2-d.

DOI:10.1002/1097-0142(19851115)56:10<2420::aid-cncr2820561014>3.0.co;2-d
PMID:2412684
Abstract

Bleomycin was administered in a phase II trial to 10 patients with malignant ascites. Complete responses to intraperitoneal bleomycin were observed in 6/10 patients (60%). Pharmacokinetics of serum and intraperitoneal bleomycin showed peak levels at 15 minutes with a peritoneal fluid half-life of 4.2 +/- 0.1 hours and a serum half-life of 5.0 +/- 1.2 hours. There was a 400-fold difference in concentration when bleomycin was administered intra-abdominally. Toxicities with intraperitoneal bleomycin were minimal. This phase II trial confirms the efficacy of intraperitoneal bleomycin; further trials appear warranted.

摘要

相似文献

1
Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial.
Cancer. 1985 Nov 15;56(10):2420-3. doi: 10.1002/1097-0142(19851115)56:10<2420::aid-cncr2820561014>3.0.co;2-d.
2
Intracavitary bleomycin in the management of malignant effusions.腔内注射博来霉素治疗恶性胸腔积液
Cancer. 1976 Nov;38(5):1903-8. doi: 10.1002/1097-0142(197611)38:5<1903::aid-cncr2820380506>3.0.co;2-a.
3
Malignant peritoneal mesothelioma after Thorotrast exposure.
Am J Clin Oncol. 1995 Aug;18(4):313-7. doi: 10.1097/00000421-199508000-00009.
4
Phase II evaluation of bleomycin in patients with advanced epithelial ovarian cancer.
Cancer Treat Rep. 1984 Mar;68(3):549-50.
5
Pharmacokinetics of bleomycin after im administration in man.博来霉素在人体肌内注射后的药代动力学
Cancer Treat Rep. 1981 May-Jun;65(5-6):485-9.
6
Pharmacologic data and technical feasibility of intraperitoneal doxorubicin administration.
Tumori. 1985 Feb 28;71(1):63-8. doi: 10.1177/030089168507100112.
7
Intraperitoneal bleomycin for sarcomatosis-related malignant ascites: Prolonged symptom relief.
Pediatr Blood Cancer. 2015 Oct;62(10):1868-9. doi: 10.1002/pbc.25527. Epub 2015 Apr 1.
8
Intraperitoneal chemotherapy with melphalan.
Ann Intern Med. 1984 Jul;101(1):14-8. doi: 10.7326/0003-4819-101-1-14.
9
Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26).
Eur J Cancer Clin Oncol. 1989 May;25(5):815-20. doi: 10.1016/0277-5379(89)90126-0.
10
Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites.腹腔内注射重组人肿瘤坏死因子α对恶性腹水的影响。
Eur J Cancer. 1991;27(2):121-5. doi: 10.1016/0277-5379(91)90467-r.

引用本文的文献

1
Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.恶性腹水：预后因素、病理生理学和治疗措施的综述。
World J Gastrointest Surg. 2012 Apr 27;4(4):87-95. doi: 10.4240/wjgs.v4.i4.87.
2
Immunocytochemical detection of P-glycoprotein in the management of malignant effusions.免疫细胞化学检测P-糖蛋白在恶性胸腔积液管理中的应用
J Cancer Res Clin Oncol. 1997;123(8):456-60. doi: 10.1007/BF01372551.